Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 06, 2016 11:36 PM ET

Pharmaceuticals

Company Overview of Mersana Therapeutics, Inc.

Company Overview

Mersana Therapeutics, Inc. engineers antibody-drug conjugates that maximize the potential of new and established therapeutic classes. The company develops a portfolio of antibody-drug conjugates to improve patient outcomes in multiple oncology indications. Its clinical-stage product candidates include XMT-1001, a “tecan” conjugate for patients with lung cancers; and XMT-1107, an anti-angiogenic conjugate for patients with refractory, advanced solid tumors. The company’s conjugation system provides benefits for the development of drugs across therapeutic modalities, including antibody-drug conjugates, antibody fragments, small molecules, biologics, and synergistic drug combinations. Mersana T...

840 Memorial Drive

Cambridge, MA 02139

United States

Founded in 2001

Phone:

617-498-0020

Fax:

617-498-0109

Key Executives for Mersana Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 51
Executive Chairman
Age: 50
Vice President of Finance
Chief Business Officer
Compensation as of Fiscal Year 2015.

Mersana Therapeutics, Inc. Key Developments

Mersana Therapeutics and Takeda Pharmaceutical Company Limited Enter into New Strategic Partnership

Harris & Harris Group, Inc. noted the announcement by its portfolio company, Mersana Therapeutics, that Mersana and Takeda Pharmaceutical Company Limited have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana’s Fleximer® antibody-drug conjugate (ADC) platform and grants Mersana an option at the end of Phase 1 to co-develop and co-commercialize one of these programs in the United States. In addition, the companies will co-develop new payloads for use with ADCs. XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumors, including breast, gastric and non-small cell lung cancers. Mersana will receive an upfront payment of $40 million and an additional payment of $20 million upon clearance of the IND (Investigational New Drug application) for XMT-1522 by the FDA. Subject to the success of the XMT-1522 and ADC programs, Mersana is eligible to receive milestone payments of more than $750 million combined, as well as royalties.

Mersana Therapeutics, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 03:15 PM

Mersana Therapeutics, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 03:15 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Anna Protopapas, Chief Executive Officer, President and Director.

Mersana Therapeutics, Inc. Presents at 22nd Annual NewsMakers in the Biotech Industry Investment Conference, Sep-10-2015 01:30 PM

Mersana Therapeutics, Inc. Presents at 22nd Annual NewsMakers in the Biotech Industry Investment Conference, Sep-10-2015 01:30 PM. Venue: Millennium Broadway Hotel & Conference Center - Breakout Room 401, 145 West 44th Street, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
Warrick Pharmaceuticals Corporation United States
COLD-fX Pharmaceuticals (USA), Inc. United States
Iroko Pharmaceuticals, LLC United States
Smith-Collins Pharmaceutical, Inc. United States
Zoller Laboratories, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
February 20, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Mersana Therapeutics, Inc., please visit www.mersana.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.